Categories
Change Password!
Reset Password!
A prospective, 24-week, randomized, interventional, double-blind, monocentric, placebo-controlled study was conducted to determine the efficacy of GP-SOD associated with NB-UVB to treat non-segmental vitiligo.
In people
suffering from vitiligo, the use of gliadin-protected superoxide dismutase
(GP-SOD) combined with narrowband
ultraviolet B (NB-UVB) was found to be a valuable add-on with excellent
tolerability and safety.
A
prospective, 24-week, randomized, interventional, double-blind, monocentric,
placebo-controlled study was conducted to determine the efficacy of GP-SOD
associated with NB-UVB to treat non-segmental vitiligo.
The study
incorporated 50 patients with vitiligo affecting >5% of the total body
surface. Participants were given GP-SOD (1g per day for 12 weeks followed by
0.5g per day for 12 weeks, n=25) or placebo (n=25) in combo with twice-weekly
sessions of phototherapy. The major outcome ascertained was total
repigmentation rate at 24 weeks, in comparison with baseline, as evaluated by
Vitiligo Extent Score (VES) on the standardized pictures.
Following 24 weeks, a higher improvement in VES was witnessed in the GP-SOD arm when compared with the placebo arm, as illustrated in Table 1:
In both groups, there was good tolerance and no side
effects.
The combination of GP-SOD and NB-UVB therapy is
effective for managing vitiligo patients.
Journal of the European Academy of Dermatology and Venereology
Oral gliadin-protected superoxide dismutase in addition to phototherapy for treating non-segmental vitiligo: A 24-week prospective randomized placebo-controlled study
E Fontas et al.
Comments (0)